Skip to main content
The Flux Daily
PoliticsPurdue Pharma, the maker of OxyContin, is expected to forfeit $225 million following a settlement with the Justice Department over its role in the opioid crisis. This penalty will pave the way for a larger agreement requiring the Sackler family to pay up to $7 billion to various governments and victims, though the legal repercussions for family members remain a point of contention.

Purdue Pharma Sentencing Paves Path for Opioid Crisis Settlement

Purdue Pharma faces a pivotal $225 million judgment from the Justice Department, setting the stage for a significant settlement amid thousands of lawsuits tied to the opioid epidemic.

Source: AP2 min read
Purdue Pharma Sentencing Paves Path for Opioid Crisis Settlement
Image via AP

In brief

A judge is expected to enforce a $225 million forfeiture against Purdue Pharma, aligning with a 2020 agreement related to their role in the opioid crisis. This financial penalty could lead to a comprehensive settlement involving the Sackler family, aiming to funnel up to $7 billion toward opioid crisis mitigation and victim compensation. Despite settling, families of victims continue to advocate for accountability and further legal actions against the Sackler family.

A judge is expected to sentence OxyContin maker Purdue Pharma to forfeit $225 million to the Justice Department on Tuesday, facilitating a crucial settlement related to the opioid crisis.

This penalty is part of a previous agreement made in 2020 to resolve federal investigations. Approval by the judge will mean that other financial penalties will not be pursued, allowing Purdue to finalize its settlement from the myriad lawsuits it faces.

Months of legal proceedings culminated last year when another judge approved this comprehensive settlement, set to take effect on May 1. This significant agreement necessitates members of the Sackler family, the owners of Purdue, to pay up to $7 billion to various state, local, and Native American governments, as well as individual victims.

The Sentence: A Long Time Coming

Purdue Pharma pleaded guilty to three federal criminal charges in late 2020, acknowledging their failure to prevent OxyContin from being diverted to the black market and their financial incentives to increase prescriptions.

This case underscores not only Purdue’s complicity but emphasizes its position in the broader epidemic, given that they aggressively marketed OxyContin as a legitimate medical solution.

Purdue Pharma’s expected financial output will be $225 million, which could provide some form of restitution, but the company is not facing further criminal forfeitures or fines totaling $5.3 billion as per the plea deal.

Settlement with the Sackler Family

The broader settlement will require the Sacklers to contribute significantly over the next 15 years, directed primarily at combating the opioid crisis. This amount is featured prominently in the continuing narrative of state settlements connected to pharmaceutical companies.

Notably, these settlements exceed $50 billion collectively, offering hope for those affected by opioid addiction, with a particular focus on addressing the ongoing overdose epidemic.

However, no members of the Sackler family have been prosecuted or faced direct charges despite their substantial financial gains from Purdue's sales during the crisis.

Pushing for Justice

While 54,000 people agreed to the settlement, many victims' families, including individuals like Susan Ousterman, are advocating for more prosecution against the Sacklers. Families like hers are urging the court to pursue accountability, rather than allow the resolution to merely settle the financial aspects while leaving the painful scars of loss unaddressed.

The upcoming sentencing presents another chance for these families to express their demand for justice beyond mere settlements.

Topics

More on this story